Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

X4 Pharmaceuticals (XFOR) Accumulated Depreciation & Amortization (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $831000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Accumulated Depreciation & Amortization rose 224.61% year-over-year to $831000.0, compared with a TTM value of $831000.0 through Jun 2025, up 224.61%, and an annual FY2024 reading of $296000.0, down 29.36% over the prior year.
  • Accumulated Depreciation & Amortization was $831000.0 for Q2 2025 at X4 Pharmaceuticals, up from $476000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $831000.0 in Q2 2025 and bottomed at $62000.0 in Q1 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $339277.8, with a median of $326500.0 recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization plummeted 51.18% in 2024, then soared 667.74% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $499000.0 in 2021, then grew by 2.81% to $513000.0 in 2022, then dropped by 18.32% to $419000.0 in 2023, then dropped by 29.36% to $296000.0 in 2024, then skyrocketed by 180.74% to $831000.0 in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for XFOR at $831000.0 in Q2 2025, $476000.0 in Q1 2025, and $296000.0 in Q4 2024.